Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

GSK plc ADR diskutieren

GSK plc ADR

WKN: A3DMHS / Symbol: GSK / Name: GSK / Aktie / Pharmazeutika / Large Cap /

40,80 €
-2,39 %

GSK plc (NYSE: GSK) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating on the stock.
Ratings data for GSK provided by MarketBeat

GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for GSK provided by MarketBeat

GSK plc (NYSE: GSK) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.
Ratings data for GSK provided by MarketBeat

GSK plc (NYSE: GSK) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.
Ratings data for GSK provided by MarketBeat

GSK plc (NYSE: GSK) was upgraded by analysts at Berenberg Bank to a "strong-buy" rating.
Ratings data for GSK provided by MarketBeat

GSK plc (NYSE: GSK) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Ratings data for GSK provided by MarketBeat

Einschätzung Buy
Rendite (%) -7,39 %
Kursziel 49,33
Veränderung
Endet am 02.07.25

GSK plc (NYSE: GSK) had its price target raised by analysts at Jefferies Financial Group Inc. from $52.50 to $53.00. They now have a "buy" rating on the stock.
Ratings data for GSK provided by MarketBeat

GSK plc (NYSE: GSK) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for GSK provided by MarketBeat

GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for GSK provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,43 %
Kursziel 38,50
Veränderung
Endet am 07.02.26

Hey there! I've been keeping an eye on GSK plc ADR, and I gotta say, it's looking pretty interesting right now. With RFK Jr. potentially heading up HHS, we're in for a wild ride in the biotech world. It's like we're about to shake up a snow globe and see where all the flakes land, you know? While this might create some short-term turbulence, I think GSK's solid fundamentals and diverse portfolio could help it weather the storm and even come out stronger. It's like they're a sturdy ship in choppy waters - they might get rocked a bit, but they're built to last. Plus, at the current price, it feels like we're getting a decent deal. What do you think? Could this be a chance to grab a quality pharma stock at a discount before it potentially climbs higher?

GSK PLC Sponsored ADR (NYSE: GSK) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for GSK provided by MarketBeat